Fred Hutch/UW Hematopoietic Diseases Repository
The Fred Hutch/UW Hematopoietic Diseases Repository collects, curates and distributes samples from patients with a variety of hematologic diseases who are treated within the UWMC and SCCA Comprehensive Cancer Care Network. Since its inception in 2002, we have collected samples from hundreds of patients, many of whom have had sequential samples over the course of their treatment. Samples are available from patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), myeloproliferative disorders (MPD), myelofibrosis (MF) and myelodisplasia (MDS). Demographics, clinical variables (i.e., mutation status and clinical laboratory values), disease specifics (i.e., diagnosis, disease status, treatment plan) and clinical outcome data are available for each sample through a unique identifier in a comprehensive database system and can be made available to requesting investigators.
To request more information or an application to gain access to the Repository, please contact Era Pogosova-Agadjanyan.
The Fred Hutch/UW Hematopoietic Diseases Repository provides a very important collaborative bridge between investigators as demonstrated by the extensive list of peer-reviewed publications, abstracts and funding.
Publications | Abstracts | Grants Awarded | Grant Proposals
Publications
Last updated February 2019
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003-prior
2018
Sorror ML, Gooley TA, Maclean KH, Hubbard J, Marcondes MA, Torok-Storb BJ, Tewari M. Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality [Epub ahead of print 2 October 2018]. Bone Marrow Transplant. doi: 10.1038/s41409-018-0352-9. PMID: 30279573. PMCID: PMC Journal – In Process.
Dossa RG, Cunningham T, Sommermeyer D, Medina-Rodriguez I, Biernacki, MA, Foster K, Bleakley M. Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse. Blood. 2018;131(1):108-120. PMID: 29051183. PMCID: PMC5755045.
Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K, Ulrich M, Anderson ME, Stone IJ, Zeng W, Jonas M, Lewis TS, Goswami M, Wang SA, Senter PD, Law CL, Feldman EJ, Benjamin DR. Characterization of SGN-CD123A, a potent CD123-directed antibody-drug conjugate for acute myeloid leukemia. Mol Cancer Ther. 2018;17(2):554-564. PMID: 29142066.
Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Fang M, Kopecky KJ, List AF, Pogosov GL, Radich JP, Willman CL, Wood BL, Meshinchi S, Stirewalt DL. Impact of specimen heterogeneity on biomarkers in repository samples from patients with acute myeloid leukemia: a SWOG report. Biopreserv Biobank. 2018;16(1):42-52. doi: 10.1089/bio.2017.0079. PMID: 29172682. PMCID: PMC5808392.
Kotha S, Sun S, Adams A, Hayes B, Phong KT, Nagao R, Reems JA, Gao D, Torok-Storb B, Lopez JA, Zheng Y. Microvasculature-directed thrombopoiesis in a 3D in vitro marrow microenvironment. PLoS One. 2018;13(4):e0195082. doi: 10.1371/journal.pone.0195082. PMID: 29617409. PMCID: PMC5884538.
Kotha S, Hayes BJ, Phong KT, Redd MA, Bomsztyk K, Ramakrishnan A, Torok-Storb B, Zheng Y. Engineering a multicellular vascular niche to model hematopoietic cell trafficking. Stem Cell Res Ther. 2018;9(1):77. Doi: 10.1186/s13287-018-080-2. PMCID: 29566751. PMCID: PMC5865379.
Lee S-I, Celik S, Logsdon BA, Lundberg SM, Martins TJ, Oehler VG, Estey EH, Miller CP, Chien S, Dai J, Saxena A, Blau CA, Becker PS. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia [published online ahead of print 3 January 2018]. Nat Commun. doi: 10.1038/s41467-017-02465-5. PMID: 29298978. PMCID: PMC5752671.
2017
Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, Meshinchi S. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific interactions. Nat Med. 2018;24(1)103-112. doi: 10.1038/nm.4439. Epub 2017 Dec 11. PMCID: PMC3907936.
2016
Reusch U, Harrington KH, Gudgeon CJ, Fucek I, Ellwanger K, Weichel M, Knackmuss SH, Zhukovsky EA, Fox JA, Kunkel LA, Guenot J, Walter RB. Characterization of CD33/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia. Clin Cancer Res. 2016;22(23):5829-5838. PMID: 27189165. doi: 10.1158/1078-0432.CCR-16-0350.
Bajaj J, Konuma T, Lytle NK, Kwon HY, Ablack JN, Cantor JM, Rizzieri D, Chuah C, Oehler VG, Broome EH, Ball ED, van der Horst EH, Ginsberg MH, Reya T. CD98-mediated adhesive signaling enables the establishment and propagation of acute myelogenous leukemia. Cancer Cell. 2016;30(5):792-805. PMID: 27908736. PMCID: PMC5137811.
Laszlo GS, Harrington KH, Gudgeon CJ, Beddoe ME, Fitzgibbon MP, Ries RE, Lamba JK, McIntosh MW, Meshinchi S, Walter RB. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. Oncotarget. 2016;7(28):43281-43294. PMID: 27248327. PMCID: PMC5190023.
2015
Morris VA, Cummings CL, Korb B, Boaglio S, Oehler VG. Deregulated KLF4 expression in myeloid leukemias alters cell proliferation and differentiation through microRNA and gene targets. Mol Cell Biol. 2015;36(4):559-73. PMID: 26644403. PMCID: PMC4751692.
Qu X, Davison J, Du L, Storer B, Stirewalt DL, Heimfeld S, Estey E, Appelbaum FR, Fang M. Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia. Epigenetics. 2015;10(6):526-35. PMID: 25996682. PMCID: PMC4623036.
Kwon HY, Bajaj J, Ito T, Blevins A, Konuma T, Weeks J, Lytle NK, Koechlein CS, Rizzieri D, Chuah C, Oehler VG, Sasik R, Hardiman G, Reya T. Tetraspanin 3 is required for the development and propagation of acute myelogenous leukemia. Cell Stem Cell. 2015;17(2):152-64. PMID: 26212080. PMCID: PMC4664079.
Laszlo GS, Gudgeon CJ, Harrington KH, Walter RB. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. Blood Cancer J. 2015;5:e340. PMID: 26295610. PMCID: PMC4558592.
Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett A, List AF, Fang M, Oehler VG, Petersdorf SH, Pogosova-Agadjanyan EL, Radich JP, Willman CL, Meshinchi S, Stirewalt DL. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. J Clin Oncol. 2015;33(10):1157-64. PMID: 25713434. PMCID: PMC4372852.
Paguirigan AL, Smith J, Meshinchi S, Carroll M, Maley C, Radich JP. Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia. Sci Transl Med. 2015;7(281):281re2. PMID: 25834112. PMCID: PMC4405099.
2014
Walter RB, Laszlo GS, Lionberger JM, Pollard JA, Harrington KH, Gudgeon CJ, Othus M, Rafii S, Meshinchi S, Appelbaum FR, Bernstein ID. Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia. Leukemia. 2014;28(10):1969-77. PMID: 24721792. PMCID: PMC4167978.
Laszlo GS, Gudgeon CJ, Harrington KH, Dell’Aringa J, Newhall KJ, Means GD, Sinclair AM, Kischel R, Frankel SR, Walter RB. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123(4):554-561. PMID: 24311721. PMCID: PMC3901068.
2013
Morris VA, Zhang A, Yang T, Stirewalt DL, Ramamurthy R, Meshinchi S, Oehler VG. MicroRNA-150 expression induces myeloid differentiation of human acute leukemia cells and normal hematopoietic progenitors. PLoS One. 2013;8(9):e75815. PMID: 24086639. PMCID: PMC3782459.
Pogosova-Agadjanyan EL, Kopecky KJ, Ostronoff F, Appelbaum FR, Godwin J, Lee H, List AF, May JJ, Oehler VG, Petersdorf S, Pogosov GL, Radich JP, Willman CL, Meshinchi S, Stirewalt DL. The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia. PLoS One. 2013;8(8):e70812. PMID: 23967110. PMCID: PMC3743845.
Rosen DB, Harrington KH, Cordeiro JA, Leung LY, Putta S, Lacayo N, Laszlo GS, Gudgeon CJ, Hogge DE, Hawtin RE, Cesano A, Walter RB. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. PLoS One. 2013;8(1):e53518. PMID: 23320091. PMCID: PMC3539972.
Ostronoff F, Othus M, Kantarjian H, Meshinchi S, Ravandi F, Hendrie P, Faderl S, Becker P, Cortes J, Pagel JM, Petersdorf SH, Godwin J, Willman C, Pierce S, List A, Sandhu R, Walter R, Appelbaum F, Stirewalt D, Estey EA. A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukemia. Br J Haematol. 2013;163:130-2. PMCID: PMC4128010.
2012
Yamamura T, Hikita J, Bleakley M, Hirosawa T, Matsubara A, Hamajima T, Nannya Y, Demachi-Okamura A, Etsuko E, Saji H, Takahashi T, Emi N, Morishima Y, Kodera Y, Kuzushima K, Riddell S, Ogawa S, Akatsuka Y. HapMap SNP Scanner: an online program to mine SNPs responsible for cell phenotype. Tissue Antigens. 2012;80(2):119-25. PMID: 22568758. PMCID: PMC3635041.
Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, Hudecek M, Akatsuka Y, Weissman IL, Greenberg PD. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood. 2012;119(23):5492-501. PMID: 22529286. PMCID: PMC3369684.
Foss EJ, Radulovic D, Stirewalt DL, Radich J, Sala-Torra O, Pogosova-Agadjanyan EL, Hengel SM, Loeb KR, Deeg HJ, Meshinchi S, Goodlett DR, Bedalov A. Proteomic classification of acute leukemias by alignment-based quantitation of LC-MS/MS data sets. J Proteome Res. 2012;11(10):5005-10. PMID: 22900933. PMCID: PMC3564549.
Yeung KY, Gooley TA, Zhang A, Raftery AE, Radich JP, Oehler VG. Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression data. Bioinformatics. 2012;28(6):823-30. PMID: 22296787. PMCID: PMC3307121.
Zimmerman Z, Scott BL, Gopal AK, Sandmaier BM, Maloney DG, Deeg HJ. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy. Bone Marrow Transplant. 2012;47(6):804-9. PMID: 21909142. PMCID: PMC3237793.
2011
Fan W, Stirewalt DL, Radich JP, Zhao LP. Comparison of two methods for detecting alternative splice variants using GeneChip Exon Arrays. Int J Biomed Sci. 2011;7(3):172-180. PMID: 23675234. PMCID: PMC3614835.
Schwartz JL, Plotnik D, Slovic J, Li T, Racelis M, Deeg HJ, Friedman DL. TP53 codon-72 polymorphisms identify different radiation sensitivities to g2-chromosome breakage in human lymphoblast cells. Environ Mol Mutagen. 2011;52(1):77-80. PMID: 21038427. doi: 10.1002/em.20635. Tp53 codon-72 polymorphisms identify different radiation sensitivities to g2-chromosome breakage in human lymphoblast cells - Schwartz - 2011 - Environmental and Molecular Mutagenesis - Wiley Online Library
Si J, Mueller L., and Collins S. GSK3 inhibitors enhance retinoic acid receptor activity and induce the differentiation of retinoic acid-sensitive myeloid leukemia cells. Leukemia. 2011; 25: 1914-1918.
2010
Hudecek M, Schmitt TM, Baskar S, Lupo-Stranghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Radar C, Riddell SR. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010;116(22):4532-41. PMID: 20702778. PMCID: PMC 2996114.
Li X, Marcondes AM, Gooley TA, Deeg HJ. The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes. Blood. 2010;116(13):2304-2314. PMID: 20562331. PMCID: PMC2953837.
Bleakley M, Otterud BE, Richardt J, Mollerup M, Hudecek M, Nishida T, Chaney C, Warren EH, Leppert MF, Riddell SR. Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naïve CD8+ T cells. Blood. 2010;115(23):4923-33. PMID: 20203263. PMCID: PMC 2890170.
Campregher PV, Srivastava SK, Deeg HJ, Robins HS, Warren EH. Abnormalities of the alphabeta T-cell receptor repertoire in advance myelodysplastic syndrome. Exp Hematol. 2010;38(3):202-12. PMID: 20035823. PMCID: PMC2826587.
Marcondes AM, Li X, Gooley TA, Milless B, Deeg HJ. Identification of DJ-1/PARK-7 as a determinant of stroma-dependent and TNF-alpha-induced apoptosis in MDS using mass spectrometry and phosphopeptide analysis. Blood. 2010;115(10): 1993-2002. PMID: 20061558. PMCID: PMC2837333.
Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento W, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim SH, Kim DW, Chuah C, Oehler VG, Radich JP, Jordan CT, Reya T. Regulation of myeloid leukemia by the cell-fate determinant Musashi. Nature. 2010;466(7307):765-8. PMID 20639863. PMCID: PMC2918284.
2009
Stirewalt DL, Meshinchi S. (2009) Receptor tyrosine kinase alterations in AML - biology and therapy. In: Nagarajan L. (eds) Acute Myelogenous Leukemia. Cancer Treatment and Research, vol 145:85-108. Springer, New York, NY.
Nishida T, Hudecek M, Kostic A, Bleakley M, Warren EH, Maloney D, Storb R, Riddell SR. Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res. 2009;15(14):4759-68. PMID: 19567591. PMCID: PMC 2785487.
Marcondes AM, Bair S, Rabinovitch PS, Gooley T, Deeg HJ, Risques R. No telomere shortening in marrow stroma from patients with MDS. Ann Hematol. 2009;88(7):623-8. PMID: 19050887. PMCID: PMC2693355.
Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley T, Yang T, Epping MT, Shou Y, Pogosova-Agadjanyan E, Ladne P, Stirewalt DL, Abkowitz JL, Radich JP. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood. 2009;114(15):3299-308. PMID: 19625708. PMCID: PMC2759652.
Oehler VG, Yeung KY, Choi YE, Bumgarner RE, Raftery AE, Radich JP. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood. 2009;114(15):3292-8. PMID 19654405. PMCID: PMC2759651.
Becker PS, Kopecky KJ, Wilks AN, Chien S, Harlan JM, Willman CL, Petersdorf SH, Stirewalt DL, Papayannopoulou T, Appelbaum FR. Very late antigen-4 (VLA-4) function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood. 2009; 113:866-874. PMCID: PMC2630271.
Mhyre A, Marcondes AM, Spaulding EY, Deeg HJ. Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD. Blood. 2009;113(3):649-58. PMID: 18945969. PMCID: PMC2628371.
2008
Bar M, Stirewalt D, Pogosova-Agadjanyan E, Wagner V, Gooley T, Abbasi N, Bhatia R, Deeg HJ, Radich J. Gene expression patterns in myelodysplasia underline the role of apoptosis and differentiation in disease initiation and progression. Transl Oncogenomics. 2008;3:137-49. PMID: 20396593. PMCID: PMC2854514.
Marcondes AM, Mhyre AJ, Stirewalt DL, Kim SH, Dinarello CA, Deeg HJ. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci U S A. 2008;105(8):2865-70. PMID: 18287021. PMCID: PMC2268551.
Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan E, Engel JH, Cronk MR, Shannon- Dorcy K, McQuary AR, Hockenbery D, Wood B, Heimfeld S, Radich JR. Identification of genes with abnormal expression in acute myeloid leukemia. Genes Chromosomes Cancer. 2008;47(1):8-20. PMID: 17910043. doi: 10.1002/gcc.20500.
Meshinchi S, Stirewalt DL, Alonzo TA, Boggon TJ, Gerbing RB, Rocnik JL, Lange BJ, Gilliland DG, Radich JP. Structural and numerical variation of FLT3/ITD in pediatric AML - a report from the Children's Oncology Group. Blood. 2008;111(10):4930-3. PMID: 18305215. PMCID: PMC2384125.
Bar M, Deeg J, Stirewalt D, Bhatia R, Radich J. Gene expression patterns in myelodysplasia underline the role of apoptosis and differentiation in disease initiation and progression. Translational Oncogenomics. 2008;3:137-149. PMCID:PMC2854514.
Stirewalt DL, Mhyre AJ, Marcondes M, Pogosova-Agadjanyan E, Abbasi, N, Radich JP, Deeg HJ. Tumor necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? Br J Haematol. 2008; 140(4):444-53. PMID: 18162123. doi: 10:1111/j.1365-2141.2007.06923.x.
Si J, Collins SJ. Activated Ca++/calmodulin dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation. Cancer Res. 2008;68(10):3733-42. PMID: 18483256. PMCID: PMC2443690.
2007
Ying SX, Seal S, Abbassi N, Hockenbery DM, Kiem HP, Li X, Pagel JM, Gopal AK, Deeg HJ. Differential effects of bexatrone on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines. Leuk Lymphoma. 2007;48(5):1003-14. PMID: 17487744. doi: 10.1080/10428190701242358.
Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, Greenberg PD. Activation-induced expression of CD137 permits detection, isolation and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110(1):201-10. PMID: 17371945. PMCID: PMC1896114.
Sala-Torra O, Gundacker HM, Stirewalt DL, Ladne PA, Pogosova-Agadjanyan EL, Slovak ML, Willman CL, Heimfeld S, Boldt DH, Radich JP. Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia. Blood. 2007;109(7):3080-83. PMID: 17170128. PMCID: 1852221.
2006
Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J, Slovak ML, Willman CL, Radich JP. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood. 2006;107(9):3724-26. PMID: 16368883. PMCID: PMC1895777.
Sala-Torra O, Hanna C, Loken MR, Flowers ME, Maris,M, Ladne PA, Mason JR, Senitzer D, Rodriguez R, Forman SJ, Deeg HJ, Radich JP. Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(5):511-17. PMID: 16635786. doi: 10.1016/j.bbmt.206.01.006.
2005
Kerbauy DMB, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ. NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood. 2005;106(12):3917-25. PMID: 16105982. PMCID: PMC1895102.
Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol. 2005;175(4):2261-9. PMID: 16081794. doi: 10.4049/jimmunol.175.4.2261.
Tse W, Deeg HJ, Stirewalt D, Appelbaum FR, Radich J, Gooley T. Increased AF1q gene expression in high-risk myelodysplastic syndrome. Br. J. Haematol. 2005;128(2):218-20. PMID: 15638856. doi: 10.1111/j.1365-2141.2004.05306.x.
2004
Li X, Bryant E, Deeg HJ. Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol. 2004;80(2):140-145. PMID: 15481442.
Tse W, Meshinchi S, Alonzo TA, Stirewalt DL, Gerbing RB, Woods WG, Appelbaum FR, Radich JP. Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood. 2004;104(10):3058-63. PMID: 15217837. doi: 10.1182/blood-2003-12-4347.
Kussick SJ, Stirewalt DL, Yi HS, Sheets KM, Pogosova-Agadjanyan E, Braswell S, Norwood TH, Radich JP, Wood BL. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication. Leukemia. 2004;18(10):1591-98. PMID: 15343344. doi: 10.1038/sj.leu.2403458.
Stirewalt DL, Meshinchi S, Kussick SJ, Sheets KM, Pogosova-Agadjanyan E, Willman CL, Radich JP. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. Br J Haematol. 2004;124(4):481-484. PMID: 14984498.
Stirewalt DL, Pogosova-Agadjanyan EL, Khalid N, Hare DR, Ladne PA, Sala-Torra O, Zhao LP, Radich JR. Single-stranded linear amplification protocol results in reproducible and reliable microarray data from nanogram amounts of starting RNA. Genomics. 2004;83(2):321-331. PMID: 14706461.
Tse W, Meshinchi S, Alonzo TA, Stirewalt DL, Gerbing RB, Woods WG, Appelbaum FR, Radich JP. Elevated expression of the AF1q gene, an MLL fusion partner, is independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood. 2004;104(10):3058-63. PMID: 15217837. doi: 10.1182/blood-2003-12-4347.
2003
Benesch M, Platzbecker U, Ward J, Deeg HJ, Leisenring W. Expression of FLIP(long) and FLIP(short) in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia. 2003;17(12): 2460-2466. PMID: 14562111. doi: 1038/sj.leu.2403180.
Stirewalt DL, Willman CL, Radich JP. Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific. Leuk Res. 2001;25(12):1085-1088. PMID: 11684280.
Selected Abstracts
Last updated February 2019
2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 | 2011 | 2010 | 2008 | 2006 |2005 | 2004-prior
2019
Biernacki MA, Foster KA, Coon ME, Stokke J, Cunningham TM, Dossa RG, Brault M, Woodward KB, Gardner K, Estey E, Meshinchi S, Bleakley M. An Epitope from the Recurrent CBFB-MYH11 Fusion Protein Is a Highly Immunogenic AML Neoantigen. TCT 2019 late-breaking abstract (poster presentation).
2018
Chien SS, Dai J, Magnani JL, Sekizaki TS, Fogler WE, Thackray HM, Gardner K, Estey EH, Becker PS. E-Selectin Ligand Expression by Leukemic Blasts is Associated with Prognosis in Patients with AML. Blood 2018 132:1513. doi: https://10.1182/blood-2018-99-119449.
2017
Godwin, CD et al. Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecules APVO436 and APVO437 Have Broad Activity Against Primary Human AML Cells In Vitro. 2017. Abstract accepted at: 59th Annual Meeting of the American Society of Hematology, Atlanta, GA.
Sala-Torra O, Ries R, Meshinchi S, Cassaday R, Stirewalt D, Radich J, Yeung C. Evaluation of Archer FusionPlex Panel in hematologic malignancies. AMP Annual Meeting. 2017, TT96.
2016
Halpern AB, Estey EH, Othus M, Huebner EM, Orlowski KF, Scott BL, Perdue A, Smith H, Becker PS, Hendrie PC, Cossone S, Chen TL, Stirewalt DL, Walter RB. Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study. Annual Meeting of the American Society of Hematology. 2016, 1064.
Selim D, Alonzo T, Othus M, Gerbing R, Ostronoff F, Gamis A, Kolb EA, Stirewalt DL, Meshinchi S. Genomic subtypes of nucleophosmin mutations are associated with clinical outcome in AML – a COG and SWOG intergroup collaboration. Annual Meeting of the American Society of Hematology. 2016, 285.
Pogosova-Agadjanyan EL, Moseley A, Wood BL, Appelbaum FR, Chauncey TR, Chen IM, Erba HP, Godwin J, Fang M, Kopecky KJ, List AF, Othus M, Radich JP, Willman CL, Meshinchi S, Stirewalt DL. Improved Prognostic Significance of Genomic and Transcriptional Biomarkers by Examining Enriched Populations of AML Blasts: A SWOG Report. Annual Meeting of the American Society of Hematology. 2016, 2890.
2015
Surya S Kotha, Kiet T Phong, Amie Adams, Brian Hayes, Meredith A Roberts, Karol Bomsztyk, Aravind Ramakrishnan, Beverly Torok-Storb, Ying Zheng. "Monocyte and Fibroblast Directed Generation of a Marrow Vascular Niche" (2015): 3602-3602. American Society for Hematology.
Ostronoff F, Alonzo TA, Othus M, Kutny M, Gerbing R, Radich J, Erba H, Appelbaum FR, Kolb EA, Gamis A, Stirewalt DL, Meshinchi S. Defining the Genomic Make-Up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531, and SWOG S0106. Annual Meeting of the American Society of Hematology. 2015; 126.
Sorror ML, Gooley T, Maclean K, Roy S, Hubbard J, Marcondes M, Torok-Storb B, and Tewari M. Pre-Transplant Expressions of MicroRNAs Are Associated with Both Comorbidity Burden and Mortality Risks in Patients (Pts) with Acute Leukemia (AL) in Complete Remission (CR) Given Allogeneic Hematopoietic Cell Transplantation (HCT). Blood. 2015.
2013
Ostronoff F, Othus M, Meshinchi S, Godwin JE, Kopecky KJ, List A, Oehler VG, Petersdorf S, Pogosova-Agadjanyan EL, Radich J, Willman CL, Appelbaum FR, Stirewalt DL. Prognostic Significance of NPM1 mutations In the Absence of FLT3-ITD in Older Patients With AML: A SWOG Report. Annual Meeting of the American Society of Hematology. Blood, 2013; 122.
2012
Ochsenreither S, Majeti R, Loeb K, Stirewalt DL, Keilholz U, Weissman IL, Greenberg PD. Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells. Annual Meeting of the American Society of Clinical Oncology, JCO. 2012; 30.
Ostronoff F, Othus M, Kantarjan HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf S, Godwin JE, Willman CL, Pierce SA, List AL, Sandhu RK, Walter RB, Stirewalt DL, Appelbaum FR, Estey EH. A scoring system for prediction of FLT3-ITD positivity in patients with newly diagnosed acute myeloid leukemia. Annual Meeting of the American Society of Hematology, Blood. 2012; 120:2590.
Stirewalt DL, Alonzo TA, Pogosova-Agadjanyan EL, Gerbing RB, Franklin J, Raimond SC, Hirsch BA, Gamis AS, Meshinchi S. Novel IL23R splice variant is associated with worse prognosis in pediatric patients with AML. Annual Meeting of the American Society of Hematology, Blood. 2012; 120:2546
Stirewalt DL, Alonzo TA, Pogosova-Agadjanyan EL, Gerbing RB, Franklin J, Lee H, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S. Novel IRF8 splice variants are validated as a new prognostic biomarker for adverse outcome in an independent population of pediatric patients with AML. Annual Meeting of the American Society of Hematology, Blood. 2012; 120:2550.
Ochsenreither S, Majeti R, Stirewalt D, Loeb KR, Keilholz U, Greenberg P. Cyclin-A1: A novel cancer-testis antigen in acute myeloid leukemia stem cells. Onkologie. 2012; 35: 163.
Paguirigan A, Smith J, and Radich J. Single cell assays of heterogeneity and clonality in leukemia. Annual Meeting of the American Association for Cancer Research 2012. Chicago, IL.
Morris VA, Zhang A, and Oehler VG. MicroRNA-150 expression induces differentiation of myeloid leukemias. Annual Meeting of the American Association for Cancer Research 2012. Chicago, IL.
2011
Paguirigan A, and Radich J. 2011. Development of multiplexed single cell expression and genotyping assays to assess intercellular variability, sample heterogeneity and clonality in AML and CML patient samples. AACR Conference on Stem Cells, Development and Cancer. Vancouver, BC.
Fang M, Qu X, Davison D, Du L, Appelbaum F, Estey E. Identification of Differential Methylation Markers Among Cytogenetic Risk Groups of Acute Myeloid Leukemia American Society of Hematology annual meeting, Blood. 2011; 118: 1464.
Pogosova-Agadjanyan EL, Meshinchi S, Wood B, Stirewalt DL. Expression Differences of Prognostic Biomarkers in Mononuclear Cells (MNCs) and Malignant Blasts of Acute Myeloid Leukemia (AML) Patients. American Society of Hematology annual meeting, Blood. 2011; 118: 1468.
Pogosova-Agadjanyan EL, Kopecky KJ, Lee H, Anderson J, Godwin J, List AF, Meshinchi S, Oehler VG, Petersdorf S, Willman C, Appelbaum F, Radich JR, Stirewalt DL. Over-expression of Novel IRF8 Splice Variants is Associated with a Significant Decrease in Relapse-Free Survival in adult AML Patients. American Society of Hematology annual meeting, Blood. 2011; 118: 1679.
Chien S, Basu S, Zhao X, Becker PS. Adhesion Receptor Expression by Leukemia Stem Cells in Acute Myeloid Leukemia: Relevance to Interaction with the Bone Marrow Stromal Microenvironment. ISEH meeting, August 2011.
Pogosova-Agadjanyan EL, Kopecky KJ, Meshinchi S, Petersdorf S, Erba HP, Stone RM, Meshinchi S, Nevill TJ, Radich JP, Stenke L, Slovak M, Stuart RK, Tallman MS, Willman CL, Mortensen RM, Wentz BL, Appelbaum FR, Stirewalt DL. Prognostic significance of FLT3 and NPM1 mutations in adults age 18 – 60 with de novo acute myeloid leukemia (AML) on SWOG S0106 study: a study by FHCRC and SWOG. Annual Meeting of the American Society of Hematology, Blood. 2011; 118:2520.
2010
Pogosova-Agadjanyan EL, Lee H, Cummings CK, Meshinchi S, Radich JR, Stirewalt DL. Methylation Regulates Expression of Novel Splice Variant and Wild Type Transcripts of IRF8. American Society of Hematology annual meeting, Blood. 2010; 116: 3634.
Morris VA, Yang T, Ladne P, Radich JP, Oehler VG. MicroRNA-150 is down-regulated in chronic myeloid leukemia and microRNA-150 expression promotes myeloid differentiation. American Society of Hematology annual meeting, Blood. 2010;116: abstract 1213.
Oehler VG, Walter RB, Cummings C, Sala-Torra O, Stirewalt DL, Fan M, Radich JP, Wood B. CD52 expression in leukemic stem/progenitor cells. American Society of Hematology annual meeting, Blood. 2010; 116: 2743.
2008
Bleakley M, Nishida T, Otterud B, Riddell SR. Discovery of Leukemia Associated Minor Histocompatibilty Antigens Using CD8+ T cell clones Isolated by Primary in Vitro Stimulation of Naïve T cells. Biology of Blood and Marrow Transplantation February 2008 (Vol. 14, Issue 2, Pages 10-11).
Oehler V, Cummings C, Sabo K, Wood B, Guthrie K, Gooley T, Pogosova-Agadjanyan E, Ladne P, Stirewalt DL, Abkowitz JL, Radich J. Preferentially Expressed Antigen in Melanoma (PRAME) Expression in Normal and CML CD34+ Progenitor Cells Impairs Myeloid Differentiation. American Society of Hematology annual meeting, Blood. 2008; 112: 1071.
2006
Wolfl M, KuballJ, Ho W, Nguyen H, Manley T, Bleakley M, Greenberg P. Expression of CD137 following antigen-stimulation allows for detection, isolation and expansion of antigen-specific CD8+ T cells: a novel tool for epitope discovery. Cancer Immunotherapy Meeting New York 2006.
2005
Sala-Torra O, Gundacker HM, Stirewalt DL, Ladne PA, Pogosova-Agadjanyan EL, Slovak ML, Willman CL, Heimfeld S, Boldt DH, Radich JP. CTGF predicts OS and DFS in adult acute lymphoblastic leukemia. American Society of Hematology annual meeting, Blood. 2005; 106: 336.
2004
Tse W, Deeg HJ, Stirewalt D, Appelbaum FR, Radich J, Gooley T. Increased AF1q gene expression in high-risk myelodysplastic syndrome. Br. J. Haematol. 128: 218-220, 2004.
Mendelin JE, Stirewalt DL, Yi HS, Sheets KM, Radich JP, Wood BL. Acute myeloid leukemias bearing the Flt3 internal tandem duplication have a characteristic immunophenotype not shared by acute myeloid leukemias with activating point mutations in FLT3 or RAS genes. American Society of Clinical Pathologists annual meeting, AJCP 2004; 122:466.
2003
Stirewalt DL, Pogosova-Agadjanyan EL, Khalid N, Kussick S, Ladne PA, Sheets K, Zhao LP, Radich JP. Gene Expression Differences between AML Cells and Normal CD34+ and Bone Marrow Cells. American Society of Hematology annual meeting, Blood. 2003; 102: 4495.
Tse WW, Meshinchi S, Alonzo TA, Stirewalt DL, Banker DE, Woods WG, Appelbaum FR, Radich JP. Elevated expression of AF1q gene, and MLL gene fusion partner, is an independent adverse prognostic marker for pediatric acute myeloid leukemia. American Society of Hematology annual meeting, Blood. 2003; 102: 1352.
2002
Stirewalt DL, Pogosova-Agadjanyan EL, Khalid N, Hare DR, Ladne PA, Sala-Torra O, Zhao LP, Radich JP. Single-stranded linear amplification protocol (“SLAP’) results in reproducible and reliable microarray data from nanogram amounts of starting RNA. NCI Director Challenge Meeting. 2002; #37.
Bellido M, Stirewalt DL, Pogosova EL, Kussick S, Sala O, Deeg J, Radich JP. Comparison of differentially expressed genes between AML and RAEBt using two different software for data analysis. American Society of Hematology annual meeting, Blood. 2002; 100: 4314.
Grants Awarded
Last updated February 2019
Though not all encompassing, this list of grants related to the use of material from the Fred Hutch/UW Hematopoietic Diseases Repository is representative of the scope of work impacted by the Repository.
2018 – 2023
NIH/NCI R01 CA226172 (Co-PI: Paguirigan A, Radich J, Chiu D) "Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia.” $2,345,000 total direct costs.
2018 – 2023
NIH/NCI R01 CA175008 (PI: Radich J) “Understanding and Predicting Relapse in Acute Leukemia by Endogenous Molecular Network Dynamics.” $237,500 direct costs/year.
2018 – 2021
SBIR TwinStrand Biosciences (PI: Radich J) “Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing.” $262,261 direct costs/year.
2018 – 2020
NCCN Foundation Young Investigator Award (PI: Yeung CS) “Optimization of a Rapid Point of Care Device for Acute Promyelocytic Leukemia Diagnosis and Therapy Guidance.” $69,070 direct costs/year.
2018 – 2019
Pfizer Investigator-Initiated Research Award (PI: Yeung CS) ““Preclinical Validation with Chemosensitivity Testing of Glasdegib in Combination with Inotuzumab Ozogamicin for A Phase 1 Study in Patients with Relapsed or Refractory CD22 positive Acute Lymphoblastic Leukemia.” $207,129 direct costs.
2017 – 2020
AACR/SU2C Award (PI: Bleakley M) “T Cell Immunotherapy for Core Binding Factor Acute Myeloid Leukemia.” $227,272 direct costs/year.
2017 – 2019
Hyundai Hope on Wheels 2017 Scholars Hope Grant (PI: Yeung CS) “Multiplex iPCR in a Point of Care Device for Pediatric Acute Leukemia.” $125,000 direct costs/year.
2017 – 2019
Cookies for Kids Award (PI: Bleakley M) “Immunotherapy for Infant Leukemia.” $100,000 direct costs/year.
2017 – 2019
MPN (Co-PI: Oehler V, Bleakley M) “Myeloproliferative Neoplasms Research Foundation Challenge Application.” $92,593 direct costs/year.
2017 – 2019
NIH/NCI U10 CA180861 (MPI: Bloomfield, Garraway, Marcucci, Radich) “Integrated Translational Science Center for Leukemia (ITSC-L)”. Pilot Project 4 (PI: Stirewalt DL) “Validation of Proteomic Biomarkers for AML Patients Treated on SWOG Trials.” $200,000 total costs.
2017 – 2019
NIH/NCI U10 CA180861 (MPI: Bloomfield, Garraway, Marcucci, Radich) “Integrated Translational Science Center for Leukemia (ITSC-L)” Pilot Project (PI: Radich J) “Novel Molecular Strategies for NCTN ’Individualized’ Therapies.” $24,245 direct costs/year.
2017 – 2019
Juno Immunotherapy Innovation Grant (Co-PI: Chapuis AG, Stirewalt DL) “Unraveling the Peptide Presentation Landscape to Inform HLA-Restricted Immune Targeting in AML.” $333,333 total costs.
2017 – 2018
American Society of Hematology Award (PI: Oehler V) “Using miRNAs to Improve Risk-Stratification and Therapy of Pediatric AML.” $250,000 direct costs/year.
2016 – 2021
NIH/NCI R01 CA190661 (PI: Stirewalt DL) “Novel Biomarkers to Risk-Stratify AML Patients with NPM1pos/FLT3-ITDneg Genotype.” $2,717,853 total costs.
2016 – 2019
Leukemia Lymphoma Society. (PI: Bleakley M) “Prevention of Relapse after Stem Cell Transplantation by Minor H Antigen T Cell Immunotherapy.”
2016 – 2018
Pfizer Aspire Award WI210158 (PI: Oehler V) “Mechanisms Contributing to Response and Tolerance of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients.” $138,833 direct costs/year.
2015 – 2020
NIH/NCI P01 CA077852 (PD/PI: Monnat RJ) “Molecular Determinants of Cancer Therapeutic Response”; (Co-I: Becker P) Lead of Experimental Hematology Core & Co-I in each of 3 projects. $68,947 direct costs/year (Becker lab).
2015 – 2017
Gregory Fund AML Proteomic Pilot Project (Co-PI: Stirewalt DL, Paulovich A, Radich JP) “Identifying a Proteomic Signature of Non-responders in AML.” $306,886 total direct costs; $540,119 total costs.
2013 – 2019
NIH/NCI R01 CA175215 (PI: Radich J) “Single-Cell Methods for Analysis of Clonal Heterogeneity and Evolution in Cancer.” $476,705 direct costs/year.
2013 – 2018
NIH/NCI R01 CA175008 (PI: Radich J) “The Genetics of Post-Transplant Relapse in Myeloid Malignancy.” $207,500 direct costs/year.
2012 – 2018
NIH/NCI R01 CA160872 (PI: Stirewalt DL) “Discovery and Optimization of AML Prognostic Biomarkers.” $2,468,446 total costs.
2012 – 2014
NIH/NCI R21 CA164545 (PI: Bedalov A) “Proteome Biomarkers in Childhood AML.” $161,443 direct costs/year.
2011 – 2016
NIH/NCI K23 CA 154532 (PI: Bleakley M) “Allogeneic Stem Cell Transplant with Grafts Depleted of Naïve T Cells for Leukemia.” $157,028 direct costs/year.
2011 – 2014
Damon Runyon Clinical Investigator Award (PI: Bleakley M) “Segregating the GVL Effect from GVHD in Humans,” competitive renewal option for further two years. $150,000 direct costs/year.
2011 – 2013
SWOG HOPE Foundation (PI: Fang M) “Identification of Differentially Methylated Genomic Regions that are Prognostically Significant in Acute Myeloid Leukemia.” $200,000 direct costs/year.
2011 – 2012
CCEH P30 DK056465-13 (PI: Stirewalt DL) “Development of Innovative Methods to Use RNA Sequencing to Detect Novel AML-Specific Transcripts.” $20,000 direct costs/year.
2011 – 2012
NIH/NCI P30 CA 15704-37 (PI: Corey L) Cancer Center Support Grant, Sub-Project: (Project Leader: Radich J) “Genomics of Primary Refractory AML”. $400,000 direct costs/year.
2010 – 2015
NIH/NIDDK K08 DK 085156 (PI: Marcondes M) “Transcriptional Control of Stroma Dependent Apoptosis in MDS” $123,108 direct costs/year.
2010 – 2015
NIH/NCI R01 CA149566 SUB (PI: Carroll M) “Stem Cells, Differentiation and Therapeutic Resistance in AML.” $144,508 direct cost/year.
2010 – 2011
Paul Calabresi Career Development Award (NCI K12 CA079630) (PI: Bleakley M) “Allogeneic Stem Cell Transplant with Grafts Depleted of Naive T Cells for Leukemia.” $157,000 direct costs/year.
2009 – 2014
NIH/NCI R01 CA140371 (PI: Oehler VG) “Integrating Diagnostics with Therapeutic Strategies in Chronic Myeloid Leukemia.” $207,500 direct costs/year.
2009 – 2012
FDN ASH (PI: Oehler VG) “Progression and Resistance in Chronic Myeloid Leukemia.” $75,000 direct costs/year.
2009 – 2012
NIH/NIGMS R01 GM084163 SUB (PI: Yeung KY) “Prediction and Network Construction Using High-Throughput Data.” $45,559 direct costs/year.
2009 – 2011
NIH/NCI R21CA139256 (PI: Stirewalt DL) “IRF8 as a Biomarker of Aging, Malignant Transformation, and AML Prognosis.” $150,000 direct costs/year.
2008 – 2011
Leukemia and Lymphoma Translational Research Program Grant 6031-09 (PI: Becker P) “Extricating Leukemia Stem cells from the Bone Marrow Microenvironment.” $200,000 direct costs/year
2008 – 2010
American Society of Bone Marrow Transplant/Millennium New Investigator Award Leukemia and Lymphoma Society Special Fellow in Clinical Research Award (PI: Bleakley M) “Targeting T cell Alloreactivity to Promote the Graft Versus Leukemia Effect.: $30,000 costs/year.
2008 – 2010
SWCRF (PI: Collins S) “CRAC channel regulations of myeloid leukemia cell proliferation.” $100,000 direct costs/year.
2007 – 2012
NIH/NCI P01 CA18029-36 (PI: Appelbaum F) Adult Leukemia Research Center, Sub-Project 4 (Project Leader: Radich J) “Resistance and Relapse in Chronic Myeloiod Leukemia.” $164,002 direct costs/year.
2007 – 2011
FDN LLS 6160-08 (PI: Oehler VG) “Expression, Function, and Regulation of Genes Associated with Chronic Myeloid Leukemia Progression and Imatinib Mesylate Resistance.” $180,018 direct costs/year.
2005 – 2010
NIH/NCI R01 CA114563 (PI: Meshinchi S) “Prognostic Implications of FLT3 Mutations in AML.” $306,957 direct costs/year.
2005 – 2010
NIH/NHLBI R01 HL082941 (PI: Deeg HL) “Cell Death and Clonal Survival in Myelodysplastic Syndrome.” $1,000,000 direct costs/year.
2005 – 2008
Leukemia and Lymphoma Society of America Special Fellow in Clinical Research Award LLS 4452-09 (PI: Bleakley M) “Targeting T cell Alloreactivity to Promote the Graft Versus Leukemia Effect.” $61,905 direct costs/year.
2005 – 2007
CCEH P30 DK56465 (PI: Stirewalt DL) “Age-related Expression Changes in CD34+/CD38- Cells from Normal Donors.” $20,000 direct cost/year.
2005 – 2007
National Marrow Donor Program, Amy Strelzer Manasevit Award Post-Doctoral Fellowship Award (PI: Bleakley M) “Targeting the Leukemic Stem Cell: Development of a Novel Therapeutic Strategy to Prevent and Treat Leukemic Relapse Following Allogenic Stem Cell Transplant.” $35,000 direct costs/year.
2005 – 2007
National Blood Foundation Fellowship Award (PI: Bleakley M) “Discovery of Antigens for Targeted Therapy of Leukemia.” $25,000 direct costs/year.
2003 – 2005
NIH/NCI P20 CA10378 Seattle Cancer and Aging Program, Pilot Project 3 (PI: Stirewalt DL) “Surrogate Markers of Cancer Susceptibility in Older Adults.” $56,143 direct costs/year.
2003 – 2005
NIH/NCI R21 CA102624 (PI: Meshinchi S) “Prognostic Implications of FLT3 Mutations in AML.” $100,000 direct costs/year.
2002 – 2007
NIH/NCI Career Development Award, K23 CA 92405 (PI: Stirewalt DL) “An Examination of FLT3 Mutations in Acute Myeloid Leukemia.” $123,750 direct costs/year.
Grant Proposals (Recently Submitted)
2019 – 2020
NIH/NCI U10 CA180861 (MPI: Bloomfield, Garraway, Marcucci, Radich) “Integrated Translational Science Center for Leukemia (ITSC-L)” Subproject (PI: Radich J) “Novel Molecular Strategies for NCTN ‘Individualized’ Therapies.” $228,527 direct costs/year.
2019 – 2024
NIH/NCI P50 CA240156 Specialized Programs of Research Excellence (SPOREs) in Human Cancers (PI: Estey E) “AML: Pathophysiologies and Management.” $7,000,000 total direct costs.
2019 – 2024
NIH/NCI R01 CA114563 (PI: Meshinchi S): “Biology and Prognostic Implications of FLT3 Mutations in AML.” $276,825 direct costs/year.
© 2025 Fred Hutchinson Cancer Center, a 501(c)(3) nonprofit organization.